Ezt az oldalt automatikusan lefordították, és a fordítás pontossága nem garantált. Kérjük, olvassa el a angol verzió forrásszöveghez.

Intragastric Balloon and Time-Restricted Eating for Weight Loss in Adults With Overweight or Obesity

2026. november 7. frissítette: Seher Şen, Mudanya University

Effects of Intragastric Balloon and Time-Restricted Intermittent Fasting Diet on Weight Loss and Metabolic Parameters in Adults With Overweight and Obesity

The goal of this non-randomized clinical study is to learn whether an intragastric balloon (IGB) and time-restricted eating (TRE; 16-hour daily fast with an 8-hour eating window), used alone or together, improve weight loss, body composition, and metabolic parameters in adults aged 18 to 65 years with overweight or obesity (body mass index 27.0 to 39.9 kg/m²). Participants are followed in four groups according to whether they have an IGB (placed as part of routine clinical care, not assigned by the study) and whether they choose to follow TRE: (1) standard nutrition therapy, (2) IGB plus standard nutrition therapy, (3) TRE plus standard nutrition therapy, and (4) IGB plus TRE plus standard nutrition therapy. All participants receive the same individualized energy-restricted diet, dietitian follow-up, behavioral education, and physical activity advice. Body weight and body composition are measured at baseline, 3 months, and 6 months; routine laboratory results are recorded at baseline and 6 months.

A tanulmány áttekintése

Részletes leírás

This is a prospective, single-center, non-randomized, exploratory (pilot) study with a 2×2 factorial structure. The two factors are intragastric balloon (IGB; present/absent) and time-restricted eating (TRE; yes/no). IGB placement is not a study procedure: it is performed as routine clinical care according to the physician's indication and the patient's preference, and the investigators have no role in that decision. TRE is offered in the dietetics outpatient clinic; participants who wish to follow it are allocated to the TRE groups, and those who do not are followed with standard nutrition therapy alone.

All groups receive the same frequency of dietitian visits, the same behavioral education, comparable energy targets, and the same physical activity advice (7,500 to 10,000 steps per day), so that groups differ only in IGB status and TRE. Body composition is measured by multi-frequency bioelectrical impedance analysis. Laboratory values are taken from routine clinical test results; no additional blood samples are drawn. Dietary intake is assessed with 3-day food records and physical activity with participants' smartphone step counters.

At least 15 participants per group (60 in total) are planned. Main and interaction effects of IGB and TRE will be analyzed with two-way analysis of variance or general linear models, and changes over time with repeated-measures analysis of variance or linear mixed models, adjusting for age, sex, baseline body mass index, comorbidities, physical activity, and energy intake.

Tanulmány típusa

Beavatkozó

Beiratkozás (Becsült)

60

Fázis

  • Nem alkalmazható

Kapcsolatok és helyek

Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.

Tanulmányi kapcsolat

Tanulmányi helyek

    • Yıldırım
      • Bursa, Yıldırım, Törökország (Türkiye)
        • Toborzás
        • Yıldırım Doruk Hastanesi
        • Kapcsolatba lépni:
          • Yıldırım Doruk Hastanesi Seher ŞEN, Assistant Professor
          • Telefonszám: 05393919700
          • E-mail: seher.sen@mudanya.edu.tr

Részvételi kritériumok

A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.

Jogosultsági kritériumok

Tanulmányozható életkorok

18 év (Felnőtt, Idősebb felnőtt)

Egészséges önkénteseket fogad

Nem

Tanulmányozható nemek

Összes

Leírás

Inclusion Criteria:

  • Age 18 to 65 years
  • Body mass index (BMI) 27.0 to 39.9 kg/m²; for BMI 27.0 to 29.9 kg/m², at least one obesity-related comorbidity (e.g., insulin resistance, type 2 diabetes mellitus, hypertension, dyslipidemia)
  • BMI of 27 kg/m² or higher for at least 2 years
  • History of unsuccessful non-surgical weight-loss attempts
  • Willingness to participate and written informed consent

Exclusion Criteria:

  • Inflammatory bowel disease or other inflammatory conditions of the gastrointestinal tract (including esophagitis and hiatal hernia of 2 cm or larger)
  • Previous gastrointestinal surgery
  • History of upper gastrointestinal bleeding
  • Gastroparesis
  • Severe psychiatric illness
  • Active malignancy
  • Pregnancy or breastfeeding
  • Alcohol or substance dependence
  • Physical limitation preventing exercise
  • Contraindication to intragastric balloon placement

Tanulási terv

Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.

Hogyan készül a tanulmány?

Tervezési részletek

  • Elsődleges cél: Kezelés
  • Kiosztás: Nem véletlenszerű
  • Beavatkozó modell: Tényező hozzárendelés
  • Maszkolás: Nincs (Open Label)

Fegyverek és beavatkozások

Résztvevő csoport / kar
Beavatkozás / kezelés
Aktív összehasonlító: Standard Nutrition Therapy

Participants without an intragastric balloon who receive standard energy-restricted nutrition therapy only.

Individualized balanced diet with approximately 25% energy restriction from the estimated daily energy requirement (typically 1000 to 1400 kcal/day; protein 1.0 to 1.5 g/kg/day, carbohydrate 35 to 50% and fat 25 to 35% of energy), with regular dietitian follow-up, behavioral education, and advice to walk 7,500 to 10,000 steps per day.

Aktív összehasonlító: IGB + Standard Nutrition Therapy

Participants with an intragastric balloon (IGB) placed as part of routine clinical care who receive standard energy-restricted nutrition therapy.

Individualized balanced diet with approximately 25% energy restriction from the estimated daily energy requirement (typically 1000 to 1400 kcal/day; protein 1.0 to 1.5 g/kg/day, carbohydrate 35 to 50% and fat 25 to 35% of energy), with regular dietitian follow-up, behavioral education, and advice to walk 7,500 to 10,000 steps per day.

Endoscopically placed intragastric balloon, performed as part of routine clinical care based on physician indication and patient preference; placement is not assigned by the study. Diet after placement progresses through clear liquid, full liquid, pureed, and solid stages according to routine clinical practice.

Kísérleti: TRE + Standard Nutrition Therapy

Participants without an intragastric balloon who follow time-restricted eating (TRE; 16-hour daily fast, 8-hour eating window) in addition to standard energy-restricted nutrition therapy.

Individualized balanced diet with approximately 25% energy restriction from the estimated daily energy requirement (typically 1000 to 1400 kcal/day; protein 1.0 to 1.5 g/kg/day, carbohydrate 35 to 50% and fat 25 to 35% of energy), with regular dietitian follow-up, behavioral education, and advice to walk 7,500 to 10,000 steps per day.

Daily food intake limited to an 8-hour eating window with a 16-hour fast. The recommended fasting period is 18:00 to 10:00; alternative 16-hour periods (such as 19:00 to 11:00 or 20:00 to 12:00) are allowed. Water and non-caloric beverages are permitted during the fasting period. Energy and macronutrient targets are identical to standard nutrition therapy. Duration: 6 weeks.

Kísérleti: IGB + TRE + Standard Nutrition Therapy

Participants with an intragastric balloon (IGB) placed as part of routine clinical care who follow time-restricted eating (TRE; 16-hour daily fast, 8-hour eating window) in addition to standard energy-restricted nutrition therapy.

Individualized balanced diet with approximately 25% energy restriction from the estimated daily energy requirement (typically 1000 to 1400 kcal/day; protein 1.0 to 1.5 g/kg/day, carbohydrate 35 to 50% and fat 25 to 35% of energy), with regular dietitian follow-up, behavioral education, and advice to walk 7,500 to 10,000 steps per day.

Endoscopically placed intragastric balloon, performed as part of routine clinical care based on physician indication and patient preference; placement is not assigned by the study. Diet after placement progresses through clear liquid, full liquid, pureed, and solid stages according to routine clinical practice.

Daily food intake limited to an 8-hour eating window with a 16-hour fast. The recommended fasting period is 18:00 to 10:00; alternative 16-hour periods (such as 19:00 to 11:00 or 20:00 to 12:00) are allowed. Water and non-caloric beverages are permitted during the fasting period. Energy and macronutrient targets are identical to standard nutrition therapy. Duration: 6 weeks.

Mit mér a tanulmány?

Elsődleges eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Body weight
Időkeret: Baseline, Month 3, Month 6

Kilograms, measured in light clothing without shoes (Tanita MC-780 MA)

Baseline, Month 3, Month 6
Body mass index
Időkeret: Baseline, Month 3, Month 6

Weight and height combined to report BMI in kg/m²

Baseline, Month 3, Month 6
Percent total weight loss
Időkeret: Month 3, Month 6

(Baseline weight - follow-up weight) / baseline weight × 100.

Month 3, Month 6
Percent excess weight loss
Időkeret: Month 3, Month 6

(Baseline weight - follow-up weight) / (baseline weight - ideal weight) × 100; ideal weight at BMI 25 kg/m².

Month 3, Month 6
Fat mass
Időkeret: Baseline, Month 3, Month 6

Kilograms, by multi-frequency bioelectrical impedance analysis

Baseline, Month 3, Month 6
Body fat percentage
Időkeret: Baseline, Month 3, Month 6

Percent of body weight, by bioelectrical impedance analysis

Baseline, Month 3, Month 6
Muscle mass percentage
Időkeret: Baseline, Month 3, Month 6

Percent of body weight, by bioelectrical impedance analysis

Baseline, Month 3, Month 6
Muscle mass
Időkeret: Baseline, Month 3, Month 6

Kilograms, by bioelectrical impedance analysis

Baseline, Month 3, Month 6

Másodlagos eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Fasting plasma glucose
Időkeret: Baseline, Month 6

Concentration in mg/dL from routine clinical laboratory results

Baseline, Month 6
fasting insulin (µIU/mL)
Időkeret: Baseline, Month 6

Fasting serum insulin concentration in µIU/mL, obtained from routine clinical laboratory results.

Baseline, Month 6
Glycated Hemoglobin (HbA1c)
Időkeret: Baseline, Month 6

Glycated hemoglobin (HbA1c) as a percentage of total hemoglobin, obtained from routine clinical laboratory results.

Baseline, Month 6
Total Cholesterol
Időkeret: Baseline and Month 6

Serum total cholesterol concentration in mg/dL, obtained from routine clinical laboratory results.

Baseline and Month 6
High-Density Lipoprotein (HDL) Cholesterol
Időkeret: Baseline and Month 6

Serum HDL cholesterol concentration in mg/dL, obtained from routine clinical laboratory results.

Baseline and Month 6
Triglycerides
Időkeret: Baseline and Month 6

Serum triglyceride concentration in mg/dL, obtained from routine clinical laboratory results.

Baseline and Month 6
Alanine Aminotransferase (ALT)
Időkeret: Baseline and Month 6

Serum ALT activity in U/L, obtained from routine clinical laboratory results

Baseline and Month 6
Aspartate Aminotransferase (AST)
Időkeret: Baseline and Month 6

Serum AST activity in U/L, obtained from routine clinical laboratory results.

Baseline and Month 6
Serum Iron
Időkeret: Baseline and Month 6

Serum iron concentration in µg/dL, obtained from routine clinical laboratory results.

Baseline and Month 6
Ferritin
Időkeret: Baseline and Month 6

Serum ferritin concentration in ng/mL, obtained from routine clinical laboratory results.

Baseline and Month 6
Vitamin B12
Időkeret: Baseline and Month 6

Serum vitamin B12 concentration in pg/mL, obtained from routine clinical laboratory results.

Baseline and Month 6
Folate
Időkeret: Baseline and Month 6

Serum folate concentration in ng/mL, obtained from routine clinical laboratory results.

Baseline and Month 6
Sodium
Időkeret: Baseline and Month 6

Serum sodium concentration in mmol/L, obtained from routine clinical laboratory results.

Baseline and Month 6
Potassium
Időkeret: Baseline and Month 6

Serum potassium concentration in mmol/L, obtained from routine clinical laboratory results.

Baseline and Month 6
Daily energy intake
Időkeret: Baseline and Month 6

Mean daily energy intake in kcal/day, calculated from a 3-day food record.

Baseline and Month 6
Daily Protein Intake
Időkeret: Baseline and Month 6

Mean daily protein intake in g/day, calculated from a 3-day food record.

Baseline and Month 6
Daily Carbohydrate Intake
Időkeret: Baseline and Month 6

Mean daily carbohydrate intake in g/day, calculated from a 3-day food record.

Baseline and Month 6
Daily Fat Intake
Időkeret: Baseline and Month 6

Mean daily fat intake in g/day, calculated from a 3-day food record.

Baseline and Month 6
Daily Step Count
Időkeret: Baseline and Month 6

Mean number of steps per day, reported by participants from their smartphone step counter.

Baseline and Month 6

Együttműködők és nyomozók

Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.

Tanulmányi rekorddátumok

Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.

Tanulmány főbb dátumok

Tanulmány kezdete (Tényleges)

2026. május 12.

Elsődleges befejezés (Becsült)

2026. november 15.

A tanulmány befejezése (Becsült)

2026. december 1.

Tanulmányi regisztráció dátumai

Először benyújtva

2026. november 7.

Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak

2026. november 7.

Első közzététel (Tényleges)

2026. november 13.

Tanulmányi rekordok frissítései

Utolsó frissítés közzétéve (Tényleges)

2026. november 13.

Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak

2026. november 7.

Utolsó ellenőrzés

2026. november 1.

Több információ

A tanulmányhoz kapcsolódó kifejezések

Terv az egyéni résztvevői adatokhoz (IPD)

Tervezi megosztani az egyéni résztvevői adatokat (IPD)?

NEM

IPD terv leírása

In accordance with the study protocol approved by the ethics committee and national data protection legislation (Law No. 6698 on the Protection of Personal Data), individual participant data will be accessible only to the research team and will not be shared with third parties. Aggregate results will be published in peer-reviewed journals.

Gyógyszer- és eszközinformációk, tanulmányi dokumentumok

Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz

Nem

Egy amerikai FDA által szabályozott eszközterméket tanulmányoz

Nem

Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .

Iratkozz fel